{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:30:42Z","timestamp":1793403042597,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Several guidelines recommend individualized treatment to correct severe thrombocytopenia before medium- to high-risk invasive procedures in patients with chronic liver disease, lowering the risk of bleeding. In this multi-center, prospective, non-randomized controlled cohort study, the efficacy and safety of avatrombopag, proven safe and effective in two phase III trials, was further evaluated in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This real-world study enrolled 341 chronic liver disease patients with severe thrombocytopenia scheduled for medium- and high-risk invasive procedures across 20 sites between 10 June 2021 and 25 April 2023. Avatrombopag (40 mg\/day or 60 mg\/day, treatment group) or alternatives (rhTPO, rhIL-11, Chinese patent medicine or no medication treatment, control group) were administered based on the doctor\u2019s and patient\u2019s preferences. Homogeneity was compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the per-protocol set of 293 cases (66 patients of the treatment group, 79 female patients), the treatment group showed a higher proportion of patients not requiring transfusion or rescue treatment (90.9% vs. 63.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), exhibited more patients with a platelet count of \u226550\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L (78.8% vs. 23.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and higher platelet counts [(75.6\u00a0\u00b1\u00a042.9)\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L vs. (46.4\u00a0\u00b1\u00a023.1)\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001] on the procedure day, and demonstrated lower transfusion rates (7.6% vs. 32.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), with fewer WHO \u2265 2-grade bleeding events and comparable adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Avatrombopag effectively raises platelet counts, mitigating the need for transfusions and lowering the bleeding events in real-world scenarios of Chinese chronic liver disease patients with severe thrombocytopenia during the peri-procedure period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002899","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:00:31Z","timestamp":1752163231000},"page":"9228-9238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: a prospective real-world cohort study"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-4063","authenticated-orcid":false,"given":"Fan","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui-Lian","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Tianjin Third Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Kun","family":"Meng","sequence":"additional","affiliation":[{"name":"Ultrasound and Functional Diagnosis Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[{"name":"Intervention Department, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Ultrasound, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Shun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"R1-20261030","doi-asserted-by":"crossref","first-page":"366\u2013413","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatol"},{"key":"R2-20261030","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","article-title":"AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis","volume":"161","author":"O\u2019Shea","year":"2021","journal-title":"Gastroenterol"},{"key":"R3-20261030","doi-asserted-by":"crossref","first-page":"1151\u201384","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","author":"Villa","year":"2022","journal-title":"J Hepatol"},{"key":"R4-20261030","first-page":"112\u201324","article-title":"Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients","volume":"15","author":"Poordad","year":"2011","journal-title":"J Med Econ"},{"key":"R5-20261030","first-page":"378\u201385","article-title":"The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease","volume":"23","author":"Elsaid","year":"2019","journal-title":"J Med Econ"},{"key":"R6-20261030","doi-asserted-by":"crossref","first-page":"899\u2013902","DOI":"10.1016\/j.cgh.2010.06.018","article-title":"Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease","volume":"8","author":"Giannini","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-20261030","doi-asserted-by":"crossref","first-page":"2936\u201339","DOI":"10.1111\/j.1572-0241.2000.02325.x","article-title":"Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease","volume":"95","author":"Bashour","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R8-20261030","doi-asserted-by":"crossref","first-page":"689\u201395","DOI":"10.1016\/j.cgh.2009.02.021","article-title":"Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis","volume":"7","author":"Qamar","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20261030","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.jvir.2008.11.027","article-title":"Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions","volume":"20","author":"Malloy","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"R10-20261030","doi-asserted-by":"crossref","first-page":"3\u201316","DOI":"10.1016\/j.gie.2015.09.035","article-title":"The management of antithrombotic agents for patients undergoing GI endoscopy","volume":"83","author":"Acosta","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"R11-20261030","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection","volume":"319","author":"Tang","year":"2018","journal-title":"Jama"},{"key":"R12-20261030","doi-asserted-by":"crossref","first-page":"1260\u201371","DOI":"10.4240\/wjgs.v14.i11.1260","article-title":"Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: a retrospective study","volume":"14","author":"Ding","year":"2022","journal-title":"World J Gastrointest Surg"},{"key":"R13-20261030","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.11569\/wcjd.v24.i34.4608","article-title":"Comparison of efficacy of recombinant human interleukin-11 and recombinant human thrombopoietin in treating thrombocytopenia with hypersplenism in cirrhotic patients","volume":"24","author":"Liu","year":"2016","journal-title":"World Chin J Digestol"},{"key":"R14-20261030","doi-asserted-by":"crossref","first-page":"306\u201316","DOI":"10.1111\/jvh.13655","article-title":"Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: multicentre real-world observational study","volume":"29","author":"Feng","year":"2022","journal-title":"J Viral Hepat"},{"key":"R15-20261030","doi-asserted-by":"crossref","first-page":"153700","DOI":"10.1016\/j.phymed.2021.153700","article-title":"Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment","volume":"91","author":"Zhu","year":"2021","journal-title":"Phytomed"},{"key":"R16-20261030","first-page":"362\u201367","article-title":"Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion","volume":"33","author":"Tripodi","year":"2012","journal-title":"Liver Int"},{"key":"R17-20261030","doi-asserted-by":"crossref","first-page":"1062\u201370","DOI":"10.1111\/hepr.13530","article-title":"Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching","volume":"50","author":"Furuichi","year":"2020","journal-title":"Hepatol Res"},{"key":"R18-20261030","doi-asserted-by":"crossref","first-page":"502\u201306","DOI":"10.1111\/vox.12931","article-title":"Impact of COVID-19 on blood centres in Zhejiang province China","volume":"115","author":"Wang","year":"2020","journal-title":"Vox Sanguinis"},{"key":"R19-20261030","first-page":"6986\u201393","article-title":"Qian Five Rhinoceros Gindeng (QFRG) protects against development of immune thrombocytopenia via miR-181a inhibition of TLR-4 expression","volume":"8","author":"He","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R20-20261030","doi-asserted-by":"crossref","first-page":"705\u201318","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterol"},{"key":"R21-20261030","doi-asserted-by":"crossref","first-page":"1\u201311","DOI":"10.1155\/2020\/5421632","article-title":"Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies","volume":"2020","author":"Poordad","year":"2020","journal-title":"Int J Hepatol"},{"key":"R22-20261030","first-page":"100081","article-title":"Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R23-20261030","doi-asserted-by":"crossref","first-page":"236\u201345","DOI":"10.1016\/j.gastrohep.2023.05.010","article-title":"Chronic liver disease-associated severe thrombocytopenia in Spain: results from a retrospective study using machine learning and natural language processing","volume":"47","author":"Calleja-Panero","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"R24-20261030","doi-asserted-by":"crossref","first-page":"2359\u201364","DOI":"10.1111\/j.1572-0241.2004.40047.x","article-title":"A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy","volume":"99","author":"Lawitz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R25-20261030","doi-asserted-by":"crossref","first-page":"1009612","DOI":"10.3389\/fphar.2022.1009612","article-title":"Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: a real-world study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R26-20261030","doi-asserted-by":"crossref","first-page":"717\u201332","DOI":"10.1053\/j.gastro.2023.05.046","article-title":"Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): an International, Prospective, Multicenter Observational Study","volume":"165","author":"Intagliata","year":"2023","journal-title":"Gastroenterol"},{"key":"R27-20261030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/medicina59010170","article-title":"The risk of endoscopy-related bleeding in patients with liver cirrhosis: a retrospective study","volume":"59","author":"Park","year":"2023","journal-title":"Medicina"},{"key":"R28-20261030","doi-asserted-by":"crossref","first-page":"e15133","DOI":"10.1016\/j.heliyon.2023.e15133","article-title":"Gastroesophageal variceal hemorrhage in patients with chronic liver diseases attending university of Gondar Specialized comprehensive hospital in Ethiopia: institutional based cross-sectional study","volume":"9","author":"Baye","year":"2023","journal-title":"Heliyon"},{"key":"R29-20261030","first-page":"e40418","article-title":"The clinical and endoscopic profiles of patients with Upper Gastrointestinal Bleeding (UGIB) and the role of the rockall scoring system in predicting adverse outcomes","volume":"15","author":"Anshul","year":"2023","journal-title":"Cureus"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000002899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:01:14Z","timestamp":1793401274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000002899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002899","relation":{},"ISSN":["1743-9159","1743-9191"],"issn-type":[{"value":"1743-9159","type":"electronic"},{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"2025-01-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}